Log In

Enter your username and password below

A Diabetes Cure and “Fountain of Youth” in One Drug?

Researchers at the Joslin Diabetes Center may have just found the missing link in the quest to cure diabetes.

It’s an enzyme called “Sirt3.”

You see, while it’s already widely known that insulin resistance is an early warning sign of diabetes, until recently, scientists didn’t know what caused it.

They do now…

In a report published last month in the Proceedings of the National Academy of Sciences, researchers were able to trace insulin resistance back to a single culprit – Sirt3.

It turns out that Sirt3 levels are 50% lower in humans and animals with diabetes than those without the disease.

So now the question becomes, “How can we boost Sirt3 levels in the human body?”

Well, we may not have to wait too long for a booster. Because Elixir Pharmaceuticals has already been doing some groundbreaking work with the enzyme.

Even better, Elixir’s research might extend beyond diabetes.

Let me explain…

Cornering the Sirt Enzyme Drug Market

In addition to Sirt3, Cambridge, MA-based, Elixir Pharmaceuticals, also maintains exclusive licensing rights to develop drugs involving Sirt1 and Sirt2 – enzymes involved in similar processes.

Right now, the company is preparing to conduct clinical trials on its new drug’s ability to treat type 2 diabetes.

Granted, the treatment is labeled as a Sirt1 drug. But “Sirt3 protein activators” are also mentioned in the drug’s description, which could be the first step in ultimately finding a cure.

Solid results are likely still a ways off, considering we’re only at the pre-clinical trial stage.

But when the results do hit, Wall Street will be paying very close attention – especially considering that advisory firm, Decision Resources, estimated that the drug market for type 2 diabetes should hit $36 billion in 2019. That’s an 89% increase over 2009’s $19 billion!

Take note, though… Sirt3 isn’t just tied to diabetes. Scientists found that the enzyme could be linked to cancer, hearing loss and aging, too.

So if this treatment indeed shows evidence of boosting levels of Sirt3 in the body, both consumers and Big Pharma should show huge interest.

Elixir already maintains partnerships with top pharmaceutical companies like Bristol-Myers Squibb (NYSE: BMY) and Novartis Pharmaceuticals (NYSE: NVS).

But with this drug’s potential to cure several diseases in one fell swoop, don’t be surprised if it turns other drug giants’ heads in the near future.

In the meantime, we’ll be sure to follow the trial results very closely. As always, stay tuned for updates.

Good investing,

Justin Fritz

Justin Fritz

, Executive Editor

View More By Justin Fritz